You searched for Cybin - Page 23 of 60

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Commences Trading on the OTCQB(R) Venture Market

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading on the OTCQB, Cybin has achieved another important milestone on its path to advancing mental health care through evidenced-based therapeutics. … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Commences Trading on the OTCQB(R) Venture Market”

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives

Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics … Continue reading “Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Commence Trading on the OTCQB Venture Market

Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB(R) Venture Market. Cybin will commence trading on the OTCQB under the symbol “CLXPF” at market open on March 8, 2021. “Listing on the OTCQB is another important milestone for … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Commence Trading on the OTCQB Venture Market”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work to quantify brain activity in real time during psychedelic … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences”

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments

Pure Extract Technologies pursues study into psilocybin active treatments Study to extend for 250-day period, targeting a number of milestones The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, … Continue reading “Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Announces Upcoming Conference Call, Webcast to Provide Business Update

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company focused on psychedelic pharmaceutical therapies, has scheduled a conference call and webcast for 10 a.m. ET on Wednesday, Feb. 17, 2021. Cybin CEO Doug Drysdale will conduct the call and webcast. The agenda for the call includes a review of the company’s financial results as well … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Announces Upcoming Conference Call, Webcast to Provide Business Update”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin

Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions Cybin to provide solutions amid significant demand, with more than 18 million people in the … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD”

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mind Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders Innovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering … Continue reading “Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics”

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments

Pure Extracts commences study into psilocybin-based active treatments Study set to be carried out at Toronto Institute of Pharmaceutical Technology, supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Study will delve into carrying out conformity testing, stability testing for psilocybin products thereby commencing the R&D that will ultimately take place at Pure Extracts’ purpose-built … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments”

Site Search

Company Search

Search Results for: Cybin